Journal article
Inhibitor development in previously treated hemophilia A patients: a systematic review, meta‐analysis, and meta‐regression
Abstract
BACKGROUND: The development of neutralizing alloantibodies (inhibitors) is the most serious complication of factor VIII (FVIII) replacement therapy in patients with hemophilia A. Unlike previously untreated patients, no definite risk factors for inhibitor development are known for previously treated patients (PTPs). The investigation of the development of inhibitors in PTPs is hindered by several methodological limitations in the available …
Authors
Xi M; Makris M; Marcucci M; Santagostino E; Mannucci PM; Iorio A
Journal
Journal of Thrombosis and Haemostasis, Vol. 11, No. 9, pp. 1655–1662
Publisher
Elsevier
Publication Date
September 2013
DOI
10.1111/jth.12335
ISSN
1538-7933